Dissecting mechanisms of resistance to targeted drug combination therapy in human colorectal cancer
出版年份 2019 全文链接
标题
Dissecting mechanisms of resistance to targeted drug combination therapy in human colorectal cancer
作者
关键词
-
出版物
ONCOGENE
Volume -, Issue -, Pages -
出版商
Springer Nature
发表日期
2019-03-25
DOI
10.1038/s41388-019-0780-z
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo
- (2018) Yongwei Su et al. BIOCHEMICAL PHARMACOLOGY
- A Convergence-Based Framework for Cancer Drug Resistance
- (2018) David J. Konieczkowski et al. CANCER CELL
- Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma
- (2017) Martin Dreyling et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
- (2017) Ryan J. Sullivan et al. Cancer Discovery
- Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer
- (2016) D. Oddo et al. CANCER RESEARCH
- Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development
- (2016) James F. Blake et al. JOURNAL OF MEDICINAL CHEMISTRY
- Determination of ulixertinib in mice plasma by LC–MS/MS and its application to a pharmacokinetic study in mice
- (2016) Rajinish Kumar et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- Dissecting Therapeutic Resistance to ERK Inhibition
- (2016) S. Jha et al. MOLECULAR CANCER THERAPEUTICS
- The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737
- (2016) Cécile Pétigny-Lechartier et al. MOLECULAR CANCER THERAPEUTICS
- Mutational and network level mechanisms underlying resistance to anti-cancer kinase inhibitors
- (2016) Maicol Mancini et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes
- (2015) Ana Herrero et al. CANCER CELL
- MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer
- (2015) C. Garcia-Garcia et al. CLINICAL CANCER RESEARCH
- Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer
- (2015) Ryan B. Corcoran et al. JOURNAL OF CLINICAL ONCOLOGY
- MEK and PI3K inhibition in solid tumors: rationale and evidence to date
- (2015) E. Jokinen et al. Therapeutic Advances in Medical Oncology
- ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors
- (2014) E. M. Goetz et al. CANCER RESEARCH
- Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients WithBRAFV600-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor
- (2014) Douglas B. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
- (2014) Dejan Juric et al. NATURE
- A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics
- (2014) Apirat Chaikuad et al. Nature Chemical Biology
- The clinical development of MEK inhibitors
- (2014) Yujie Zhao et al. Nature Reviews Clinical Oncology
- Targeting RAS–ERK signalling in cancer: promises and challenges
- (2014) Ahmed A. Samatar et al. NATURE REVIEWS DRUG DISCOVERY
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
- (2014) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
- (2014) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug Resistance
- (2013) D Gonzalez de Castro et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Genome-based cancer therapeutics: targets, kinase drug resistance and future strategies for precision oncology
- (2013) Paul Workman et al. CURRENT OPINION IN PHARMACOLOGY
- Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells
- (2013) Erika Martinelli et al. INTERNATIONAL JOURNAL OF CANCER
- PUMA and BIM Are Required for Oncogene Inactivation-Induced Apoptosis
- (2013) G. R. Bean et al. Science Signaling
- mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1
- (2013) A. C. Faber et al. Cancer Discovery
- MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition
- (2013) N. Wagle et al. Cancer Discovery
- Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
- (2013) E. J. Morris et al. Cancer Discovery
- The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance
- (2012) Matthew J. Sale et al. BIOCHEMICAL JOURNAL
- The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition
- (2012) E J Haagensen et al. BRITISH JOURNAL OF CANCER
- Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models
- (2012) Ryan B. Corcoran et al. CANCER CELL
- Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas
- (2012) G. Migliardi et al. CLINICAL CANCER RESEARCH
- ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors
- (2012) G. Hatzivassiliou et al. MOLECULAR CANCER THERAPEUTICS
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Circumventing Cancer Drug Resistance in the Era of Personalized Medicine
- (2012) Levi A. Garraway et al. Cancer Discovery
- Exploiting the Cancer Genome: Strategies for the Discovery and Clinical Development of Targeted Molecular Therapeutics
- (2011) Timothy A. Yap et al. Annual Review of Pharmacology and Toxicology
- Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth Inhibition
- (2011) K. P. Hoeflich et al. CANCER RESEARCH
- Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human glioma
- (2011) Sandrine Guillard et al. CELL CYCLE
- Fast and accurate long-read alignment with Burrows–Wheeler transform
- (2010) Heng Li et al. BIOINFORMATICS
- BID, BIM, and PUMA Are Essential for Activation of the BAX- and BAK-Dependent Cell Death Program
- (2010) D. Ren et al. SCIENCE
- Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941
- (2009) F. I. Raynaud et al. MOLECULAR CANCER THERAPEUTICS
- MEK1 mutations confer resistance to MEK and B-RAF inhibition
- (2009) C. M. Emery et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Discovery of Drug-Resistant and Drug-Sensitizing Mutations in the Oncogenic PI3K Isoform p110α
- (2008) Eli R. Zunder et al. CANCER CELL
- The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer†
- (2008) Adrian J. Folkes et al. JOURNAL OF MEDICINAL CHEMISTRY
- ERK and MDM2 prey on FOXO3a
- (2008) Wensheng Yang et al. NATURE CELL BIOLOGY
- ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation
- (2008) Jer-Yen Yang et al. NATURE CELL BIOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started